Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 10;16(12):e0261095.
doi: 10.1371/journal.pone.0261095. eCollection 2021.

Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain

Shumpei Obata  1 , Yusuke Ichiyama  1 , Riko Matsumoto  1 , Masashi Kakinoki  1 , Yoshitsugu Saishin  1 , Takahide Yanagi  2 , Yoshihiro Maruo  2 , Masahito Ohji  1
Affiliations

Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain

Shumpei Obata et al. PLoS One. .

Abstract

Purpose: To evaluate the short-term effect on body weight (BW) gain after intravitreal bevacizumab (IVB) for retinopathy of prematurity (ROP).

Methods: This was a retrospective 1:1 matched case-control study. Infants with ROP treated by IVB or photocoagulation (PC) at Shiga University of Medical Science Hospital between April 2010 and December 2019 were included in the study. To match BWs at treatment between the IVB and PC groups, 1:1 matching for BWs at treatment within 100 g was performed. The BW gains for the 7 days before treatment (pre-treatment week), the 7 days after treatment (first post-treatment week), and the period from 7 to 14 days after treatment (second post-treatment week) were compared between the IVB and PC groups.

Results: Following 1:1 matching, 13 infants in both groups were enrolled in the analysis. The weekly BW gain for the first post-treatment week was significantly lower in the IVB group compared with the PC group (86 g vs. 145 g; P = 0.046), whereas the weekly BW gains for the pre-treatment week (173 g vs. 159 g; P = 0.71) and the second post-treatment week (154 g vs. 152 g; P = 0.73) were comparable between the two groups. The short-term inhibitive effect of IVB on BW gain was particularly observed in infants weighing less than 1500 g at treatment (<1500 g: 47 g vs. ≥1500 g: 132 g; P = 0.03).

Conclusion: IVB could have a short-term inhibitive effect on BW gain in infants with ROP, and this effect is more likely to occur in infants with a lower BW at the time of treatment.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Patient flow diagram.
ROP, retinopathy of prematurity; IVB, intravitreal injection of bevacizumab; PC, photocoagulation.
Fig 2
Fig 2. BW pre- and post-treatment.
A, Mean BWs from 7 days before treatment to 14 days after treatment. B, Weekly BW gains for the 7 days before treatment (pre-treatment week), the 7 days after treatment (first post-treatment week), and the period from 7 to 14 days after treatment (second post-treatment week). BW gain in the IVB group during the first post-treatment week was significantly lower than that in the PC group. BW, body weight; IVB, intravitreal injection of bevacizumab; PC, photocoagulation.
Fig 3
Fig 3. Effect of Pre-treatment BW on BW gain post-treatment.
The BW gains during the first post-treatment week in infants with BW <1500 g at treatment and infants with BW ≥1500 g are shown. The BW gain in infants with BW <1500 g at treatment was significantly smaller than that in infants with BW ≥1500 g at treatment in the IVB group, but not in the PC group. BW, body weight; IVB, intravitreal injection of bevacizumab; PC, photocoagulation.
Fig 4
Fig 4. Parameters other than BW gain.
A–F, Changes in systolic (A) and diastolic (B) blood pressure, pulse rate (C), oxygen concentration set on the ventilator (D), volume of milk sucked (E), and urine output (F) from 7 days before treatment to 14 days after treatment.
See this image and copyright information in PMC

References

    1. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84(2):77–82. Epub 2008/02/01. doi: 10.1016/j.earlhumdev.2007.11.009 . - DOI - PubMed
    1. Quinn GE, Dobson V, Davitt BV, Hardy RJ, Tung B, Pedroza C, et al.. Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology. 2008;115(6):1058–64 e1. Epub 2008/04/22. doi: 10.1016/j.ophtha.2007.07.028 . - DOI - PubMed
    1. Quinn GE, Dobson V, Davitt BV, Wallace DK, Hardy RJ, Tung B, et al.. Progression of myopia and high myopia in the Early Treatment for Retinopathy of Prematurity study: findings at 4 to 6 years of age. J AAPOS. 2013;17(2):124–8. Epub 2013/04/30. doi: 10.1016/j.jaapos.2012.10.025 ; PubMed Central PMCID: PMC3725578. - DOI - PMC - PubMed
    1. McLoone E, O’Keefe M, McLoone S, Lanigan B. Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of goldmann perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus. 2007;44(3):170–3. Epub 2007/06/05. doi: 10.3928/0191-3913-20070301-10 . - DOI - PubMed
    1. Early Treatment For Retinopathy Of Prematurity Cooperative G. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684–94. doi: 10.1001/archopht.121.12.1684 . - DOI - PubMed

Publication types